Morgan McDowell
Nurse Practitioner · Lynchburg, VANPI 1801270764
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Convatec Inc. at 55.9% of the total. 2025 is the largest year on record at $5,566, 7.3 times the $761 reported in 2021. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $127.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$9K
- Sumitomo Pharma America, Inc.$2K
- AbbVie$661
- AstraZeneca$390
- Abbott$335
- Novo Nordisk$293
- plus $3K from 27 others
What the payments were for
- Consulting fees$5,05132%
- Speaking & faculty fees$9086%
- Travel & lodging$2,89819%
- Food & beverage$6,53442%
- Education$1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 32 | $8,681 |
| Sumitomo Pharma America, Inc. | 14 | $2,250 |
| AbbVie | 13 | $661 |
| AstraZeneca(2 entities) | 5 | $390 |
| Abbott | 4 | $335 |
| Novo Nordisk | 5 | $293 |
| Amgen | 4 | $275 |
| Astellas Pharma US Inc | 6 | $244 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $183 |
| GSK | 2 | $167 |
| Dexcom, Inc. | 2 | $164 |
| Rochester Medical Corporation | 5 | $138 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| Lundbeck LLC | 1 | $121 |
| Phathom Pharmaceuticals, Inc. | 1 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $111 |
| Merck | 1 | $110 |
| Bayer | 1 | $110 |
| Vertex | 2 | $105 |
| Pfizer | 3 | $102 |
| Biohaven Pharmaceuticals, Inc. | 1 | $99 |
| SK Life Science, Inc. | 1 | $96 |
| Argenx US, Inc. | 1 | $88 |
| Medtronic | 1 | $86 |
| Otsuka America Pharmaceutical, Inc. | 1 | $86 |
| Myovant Sciences Inc. | 1 | $79 |
| Biogen | 1 | $71 |
| Johnson & Johnson | 1 | $69 |
| Grifols USA, LLC | 1 | $58 |
| Urovant Sciences Inc | 1 | $49 |
| Teleflex LLC | 2 | $39 |
| CSL Behring | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENTLECATH$4,170
- Cure Catheter$1,750
- GEMTESA$1,650
- STOMAHESIVE$1,000
- GENTLECATH GLIDE$985
- FreeStyle Libre$168
- FREESTYLE LIBRE 3$127
- NEXLIZET$124
- NEXLETOL$124
- VYEPTI$121
- APTIOM$121
- Bard Urinary Drainage Bag$115
- VOQUEZNA$113
- CAPLYTA$111
- AIRSUPRA$111
- CAPVAXIVE$110
- Prolia$110
- Nubeqa$110
- FARXIGA$104
- BOTOX$102
How this compares
$15,540 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 134 | $127,157 |
| MyrbetriqMirabegron | 71 | $80,572 |
| Solifenacin Succinate | 218 | $15,241 |
| Estradiol | 204 | $13,408 |
| ImvexxyEstradiol | 23 | $5,946 |
| Tamsulosin Hcl | 287 | $4,031 |
| Trimethoprim | 68 | $2,729 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 42 | $2,584 |
| Finasteride | 177 | $2,414 |
| Methenamine Hippurate | 34 | $2,404 |
| NitrofurantoinNitrofurantoin Macrocrystal | 62 | $1,045 |
| Cephalexin | 113 | $787 |
| Oxybutynin Chloride ErOxybutynin Chloride | 34 | $781 |
| Dutasteride | 16 | $390 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 16 | $358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $2,250 | $127,157134 claims |
| Astellas Pharma US IncMyrbetriq | $244 | $80,57271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Lynchburg
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
- Kristin AustriaVirginia Beach$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.